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-eFigure 3. Major adverse cardiovascular events plus coronary revascularisation risk: Kaplan-Meier curves during the randomised trial period stratified by LDL-cholesterol levels at baseline and treatment allocation.
-eFigure 4. Coronary heart disease (definite-only coronary events) risk: Kaplan-Meier curves during the randomised trial period stratified by LDL-cholesterol levels at baseline and treatment allocation.
eFigure 5. Major adverse cardiovascular events (including coronary events as definite-only) plus coronary revascularisation risk: Kaplan-Meier curves during the randomised trial period stratified by LDL-cholesterol levels at baseline and treatment allocation.
eFigure 6. Kaplan-Meier curves for long-term (20 years) coronary heart disease death, stratified by LDL-cholesterol levels at baseline and original treatment allocation.
eFigure 7. Kaplan-Meier curves for long-term (20 years) cardiovascular death, stratified by LDLcholesterol levels at baseline and original treatment allocation.
eFigure 8. Kaplan-Meier curves for long-term (20 years) all-cause mortality, stratified by LDLcholesterol levels at baseline and original treatment allocation.
1.-SUPPLEMENTAL METHODS
Participants (men aged 45 to 64) were screened in primary care facilities in the West of Scotland district (after they were identified from doctor´s age/sex registers and invited by mail to attend non-fasting screening clinics).
S1
Fasting lipid levels were measured centrally according to the Lipid Research Clinic's protocol. S1 Those individuals with a total cholesterol level greater than or equal to 251 mg/dL (6.5 mmol/L) were given dietary advice on cholesterol reduction and invited to return in 4 weeks. S1 A complete lipoprotein analysis, including low-density lipoprotein cholesterol (LDL-C) levels, were then measured (14 hr fasting sample) during the second and third pre-enrolment screening visits. S1 Patients who had a LDL-C of 155 mg/dL (4.0 mmol/L) or higher at both screening visits with at least one measurement greater than or equal to 174 mg/dL (4.5 mmol/L) were included. Patients with LDL-C above 232 mg/dL (6.0 mmol/L) on both occasions were excluded. "Baseline lipid levels" were defined as the mean of the values measured at the second and third screening visits. There were no significant differences in lipid levels between the two screening measurements. S2 Fasting lipid levels were measured at 6-month intervals during the trial follow-up.
Participants included in the study had no evidence of prior myocardial infarction (MI) based on medical history and baseline ECG, though individuals with stable angina not hospitalized within the previous 12 months were eligible in the original trial. S1 Pre-randomisation exclusion criteria established in the original trial included: S1 (1) history of treated MI with documented ECG or enzyme changes; (2) angina pectoris requiring hospitalization for treatment or investigation within the previous 12 months (other individuals with positive Rose Questionnaire were not excluded); (3) ECG evidence of disease [Minnesota codes S3 1-1, 1-2, 1-3, 4-1, 5-1, 6-4-1, 7-1-1 or 9-6; atrial fibrillation (8-3-1)/flutter (8-3-2) , frequent (>1 in 5) ventricular premature beats, second (6-2) or third degree atrioventricular block (6-1) as well as A-V dissociation (8-6)]; (4) hypertension exceeding systolic BP >180 mmHg or diastolic BP >110 mmHg, despite treatment; (5) history of rheumatic heart disease; (6) congenital heart disease; (7) pulmonary heart disease, chronic bronchitis, emphysema or kyphoscoliosis associated with ECG changes codes 2-2, 3-2, 7-2 or 7-3; (8) cardiomegaly, congestive cardiac failure, significant valvular heart disease; (9) other suspected serious physical illness; (10) psychiatric illness (reported by GP); (11) current lipid lowering therapy; (12) biochemical and haematological laboratory exclusions: AST >60 U/L, ALT >70 U/L, Ca (adjusted) <2.1 or >2.7 mmol/L, ALP >430 U/L, protein <57 or >87 g/L, CK >360 U/L, creatinine >155 umol/L, glucose <3.0 or >10.0 mmol/L, MCV <70 or >105 fL, triglycerides >531 mg/dL (>6.0 mmol/L), haemoglobin <10 or >20 g/L, leucocyte count <2.5x10 9 or >17.0x10 9 cell/L, RBC <3.7x10 12 or >7.0x10 12 cell/L, Na <130 or >150 mmol/L, K <3.0 or >5.5 mmol/L, bilirubin >33 umol/L.
As reported previously, S1 the following endpoints are defined as follows:
Coronary heart disease (CHD) death and non-fatal myocardial infarction (MI):
1) Definite atherosclerotic CHD death: either or both of the following categories: a) Death certificate with consistent underlying or immediate cause plus one or more of the following: i) Preterminal hospitalisation with definite or suspect MI (see below). ii) Previous definite angina or suspect or definite MI when no cause other than atherosclerotic CHD could be ascribed as the cause of death. iii) Autopsy evidence of acute coronary arterial thrombosis and/or acute MI. b) Sudden and unexpected death (requires all 3 characteristics):
i) Deaths occurring within 1 hour after the onset of severe symptoms or having last been seen without them. ii) No known non-atherosclerotic acute or chronic process or event that could have been potentially lethal. iii) An "unexpected" death occurs only in a person who is not confined to his home, hospital, or other institution because of illness within 24 hours before death.
2) Definite non-fatal MI: any one or more of the following categories using the stated definitions: i) Diagnostic ECG at the time of the event.
ii) Ischaemic cardiac pain and diagnostic enzymes. iii) Ischaemic cardiac pain with both equivocal enzymes and equivocal ECG. iv) An ECG at the annual visit or at an unscheduled visit is diagnostic for MI while the previous one was not.
3) Suspect atherosclerotic CHD death: one or both of the following categories: i) Death certificate with consistent underlying or immediate cause but neither adequate preterminal documentation of the event nor previous atherosclerotic CHD diagnosis. ii) Rapid and unexpected death (requires all 3 characteristics):
(1) Death occurring between one and 24 hours after the onset of severe symptoms or having last been seen without them. (2) No known non-atherosclerotic acute or chronic process or event that could have been potentially lethal. (3) An "unexpected death" occurs only in a person who is not confined to his home, hospital or other institution because of illness within 24 hours before death.
4) Suspect MI: any one or more of the following categories using the stated definitions: i) Ischaemic cardiac pain, except when infarction is excluded by ECG or enzymes. ii) Diagnostic enzymes. iii) Equivocal ECG and equivocal enzymes. iv) Equivocal ECG alone, provided that it is not based on ST or T-wave changes only.
Cerebrovascular disease:
A single episode of motor paralysis, sensory or speech dysfunction, diplopia or visual disturbance lasting more than 1 hour, or repetitive episodes of a similar nature lasting for 5 min or more.
Extended long-term follow up
Following the final randomised trial visit pravastatin and placebo were withdrawn and patients returned to their primary care physicians. At 5 years after the completion of the randomised trial 38.7% and 35.2% of patients originally allocated to pravastatin and placebo arms, respectively, were taking statins (p<0.001) S4 . No later data on the proportion of individuals taking statin therapy were available for the subsequent years of follow-up. S4 At approximately 20 years since randomisation (15 years after the completion of the randomised trial) long-term mortality outcomes for the two original study groups (pravastatin and placebo) were compared, through linkage to electronic hospital discharge records held by the National Health Service for Scotland.
S4,S5

Adverse events
Information on adverse events during the study have been described in detail in previous publications from WOSCOPS.
S5-S8 Briefly, results at 5 years showed that the therapy with pravastatin, compared with placebo, did not unfavourably affect the liver function or produced myopathy; S6 pravastatin was found to protect from the development of diabetes S7 and from the risk of hospital admission due to cardiovascular causes without affecting non-cardiovascular hospitalizations; S8 finally, there was no evidence for an increased risk of incident fatal and non-fatal cancers, death from non-cardiovascular causes, or deaths from suicide or trauma with pravastatin.
S6
Similarly, over the 20-year period of follow-up pravastatin did not adversely affect deaths (cardiovascular, noncardiovascular, cancer) and hospitalisations (cardiovascular, non-cardiovascular) rates. S5 Unfortunately, there are no post-trial data on non-serious adverse events.
2.-SUPPLEMENTAL TABLES
eTable 1. Different definitions used in the literature for individuals with a primary elevation in LDL-C ≥190 mg/dL (≥4.91 mmol/L).
eTable 2. Total Cholesterol, HDL-Cholesterol, Non-HDL-Cholesterol and Triglyceride levels during the randomised trial period stratified by LDL-cholesterol levels at baseline.
eTable 3. Endpoints during the randomised trial period, overall and stratified by LDL-cholesterol levels at baseline.
eTable 4. Interaction tests of LDL-cholesterol and treatment for the different endpoints including LDLcholesterol as categorical (<190 and ≥190 mg/dL) or as a continuous measure for the on-trial and post-trial periods.
eTable 5. Endpoints during the extended long-term follow-up, overall and stratified by LDL-cholesterol levels at baseline, presented for the 15-year post-trial period (from end of trial to end of extended followup) and for the full 20-year follow-up period (from randomisation to end of extended follow-up).
eTable 6. Principal endpoints during the randomised trial period in subjects with LDL-cholesterol ≥190 mg/dL allocated to pravastatin.
eTable 7. CHD* and MACE* endpoints during the randomised trial period in subjects with LDLcholesterol ≥190 mg/dL allocated to pravastatin.
eTable 8. Mortality endpoints during the randomised trial period in subjects with LDL-cholesterol ≥190 mg/dL allocated to pravastatin.
eTable 9. Risk of events during the 20-year long-term follow-up in the subgroup of patients without diabetes and with a predicted 10-year ASCVD risk below 7.5% at baseline. □ LDL-C levels ≥190 mg/dL defined as FH phenotype. □ Alternative FH phenotype definitions including family history or maximally specific age-based LDL-C criteria decreased the FH phenotype prevalence but did not materially affect CHD risk estimates.
□ Sever hypercholesterolaemia, defined as having a LDL-C level ≥190 mg/dL. □ Primary, severe LDL-C elevation was defined as ≥190 mg/dL, in accordance with cholesterol guidelines (ACC/AHA 2013). □ FH is one cause of severely elevated LDL-C. Effect of therapy (vs. placebo) shown as hazard ratio (HR) and corresponding 95% confidence interval (95% CI) and p value. Note that MACE plus coronary revascularisation endpoint was used here instead of MACE alone in order to increase the number of events in each stratum and so the power of the analysis in an otherwise restricted sample to those with LDL-C ≥190 mg/dL allocated to pravastatin further stratified in different groups as shown in the table. (*) HRs are adjusted for age, history of hypertension, history of diabetes, smoking status, systolic and diastolic blood pressure, and body mass index. On-treatment LDL-C levels are defined as the mean of all LDL-C values measured after randomisation until the patient had an event or reached the end of the study. On-treatment LDL-C analyses excluded individuals with events in the first 6 months of the trial as first on-treatment LDL-C measurement was at 6 months after randomization. CHD: coronary heart disease. LDL-C: low-density lipoprotein cholesterol. MACE: major adverse cardiovascular events, defined as the composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke. To convert values for cholesterol to mmol/L, multiply by 0.02586. eTable 7. CHD* and MACE* endpoints during the randomised trial period in subjects with LDL-cholesterol ≥190 mg/dL allocated to pravastatin. Effect of therapy (vs. placebo) shown as hazard ratio (HR) and corresponding 95% confidence interval (95% CI) and p value. Note that MACE plus coronary revascularisation endpoint was used here instead of MACE alone in order to increase the number of events in each stratum and so the power of the analysis in an otherwise restricted sample to those with LDL-C ≥190 mg/dL allocated to pravastatin further stratified in different groups as shown in the table. (*) Including coronary events (i.e. non-fatal MI and CHD death) as definite only. ( †) HRs are adjusted for age, history of hypertension, history of diabetes, smoking status, systolic and diastolic blood pressure, and body mass index. On-treatment LDL-C levels are defined as the mean of all LDL-C values measured after randomisation until the patient had an event or reached the end of the study. On-treatment LDL-C analyses excluded individuals with events in the first 6 months of the trial as first on-treatment LDL-C measurement was at 6 months after randomization. CHD: coronary heart disease. LDL-C: low-density lipoprotein cholesterol. MACE: major adverse cardiovascular events, defined as the composite of cardiovascular death, non-fatal MI and non-fatal stroke. MI: myocardial infarction. To convert values for cholesterol to mmol/L, multiply by 0.02586. eTable 8. Mortality endpoints during the randomised trial period in subjects with LDL-cholesterol ≥190 mg/dL allocated to pravastatin. Effect of therapy (vs. placebo) shown as hazard ratio (HR) and corresponding 95% confidence interval (95% CI) and p value. (*) HR are adjusted for age, history of hypertension, history of diabetes, smoking status, systolic and diastolic blood pressure, and body mass index. On-treatment LDL-C levels are defined as the mean of all LDL-C values measured after randomisation until the patient had an event or reached the end of the study. On-treatment LDL-C analyses excluded individuals with events in the first 6 months of the trial as first on-treatment LDL-C measurement was at 6 months after randomization. CHD: coronary heart disease. LDL-C: low-density lipoprotein cholesterol. To convert values for cholesterol to mmol/L, multiply by 0.02586. eTable 9. Risk of events during the 20-year long-term follow-up in the subgroup of patients without diabetes and with a predicted 10-year ASCVD risk* below 7.5% at baseline. 
3.-SUPPLEMENTAL FIGURES
eFigure 1. Screening and selection of participants. WOSCOPS original study and current analyses.
eFigure 2. Low-density lipoprotein cholesterol levels during the randomised trial phase in participants without evidence of vascular disease at enrolment stratified by LDL-cholesterol levels at baseline -eFigure 3. Major adverse cardiovascular events plus coronary revascularisation risk: Kaplan-Meier curves during the randomised trial period stratified by LDL-cholesterol levels at baseline and treatment allocation.
eFigure 4. Coronary heart disease (definite-only coronary events) risk: Kaplan-Meier curves during the randomised trial period stratified by LDL-cholesterol levels at baseline and treatment allocation.
eFigure 5. Major adverse cardiovascular events (including coronary events as definite-only) plus coronary revascularisation risk: Kaplan-Meier curves during the randomised trial period stratified by LDLcholesterol levels at baseline and treatment allocation.
eFigure 6. Kaplan-Meier curves for long-term (20 years) coronary heart disease death, stratified by LDLcholesterol levels at baseline and original treatment allocation.
eFigure 7. Kaplan-Meier curves for long-term (20 years) cardiovascular death, stratified by LDLcholesterol levels at baseline and original treatment allocation. Comparisons between pravastatin and placebo arms at year 1 and at end of trail in participants with LDL-C <190 mg/dL and in participants with LDL-C ≥190 mg/dL: all p<0.001. LDL-C: low-density lipoprotein cholesterol. To convert values for cholesterol to mmol/L, multiply by 0.02586. eFigure 3. Major adverse cardiovascular events plus coronary revascularisation risk: Kaplan-Meier curves during the randomised trial period stratified by primary severe hypercholesterolaemia status at baseline and treatment allocation.
5-year follow-up Kaplan-Meier analysis for major adverse cardiovascular disease events (MACE) plus coronary revascularisation endpoint, stratified by LDL-cholesterol levels at baseline (<190 or ≥190 mg/dL) and treatment allocation at randomisation (pravastatin or placebo). Number of events in each group were as follows: placebo, LDL-C <190 mg/dL: n=128; pravastatin, LDL-C <190 mg/dL: n=95; placebo, LDL-C ≥190 mg/dL: n=134; pravastatin, LDL-C ≥190 mg/dL: n=107. MACE: major adverse cardiovascular events, defined as the composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke. CI: confidence interval. HR: hazard ratio. To convert values for cholesterol to mmol/L, multiply by 0.02586. eFigure 4. Coronary heart disease (definite-only coronary events) risk: Kaplan-Meier curves during the randomised trial period stratified by LDL-cholesterol levels at baseline and treatment allocation.
5-year follow-up Kaplan-Meier analysis for coronary heart disease (CHD) endpoint*, stratified by LDL-cholesterol levels at baseline (<190 or ≥190 mg/dL) and treatment allocation at randomisation (pravastatin or placebo). (*) Including coronary events (i.e. non-fatal MI and CHD death) as definite only. Number of events in each group were as follows: placebo, LDL-C <190 mg/dL: n=93; pravastatin, LDL-C <190 mg/dL: n=54; placebo, LDL-C ≥190 mg/dL: n=90; pravastatin, LDL-C ≥190 mg/dL: n=71. CI: confidence interval. HR: hazard ratio. To convert values for cholesterol to mmol/L, multiply by 0.02586. eFigure 5. Major adverse cardiovascular events (including coronary events as definiteonly) plus coronary revascularisation risk: Kaplan-Meier curves during the randomised trial period stratified by LDL-cholesterol levels at baseline and treatment allocation.
5-year follow-up Kaplan-Meier analysis for major adverse cardiovascular disease events (MACE) plus coronary revascularisation endpoint*, stratified by LDL-cholesterol levels at baseline (<190 or ≥190 mg/dL) and treatment allocation at randomisation (pravastatin or placebo). (*) Including coronary events (i.e. non-fatal MI and CHD death) as definite only. Number of events in each group were as follows: placebo, LDL-C <190 mg/dL: n=121; pravastatin, LDL-C <190 mg/dL: n=78; placebo, LDL-C ≥190 mg/dL: n=121; pravastatin, LDL-C ≥190 mg/dL: n=99. MACE: major adverse cardiovascular events, defined as the composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke. CI: confidence interval. HR: hazard ratio. To convert values for cholesterol to mmol/L, multiply by 0.02586. eFigure 7. Kaplan-Meier curves for long-term (20 years) cardiovascular death, stratified by LDL-cholesterol levels at baseline and original treatment allocation.
